Evotec – quarterly loss narrows, but no turnaround yet
On November 5, Evotec presented its third-quarter figures. Revenue stood at EUR 164.9 million, compared with EUR 163.9 million in the same quarter last year. Adjusted EBITDA of minus EUR 1.6 million was significantly better than the minus EUR 15.0 million recorded a year earlier. However, the group is not out of the woods yet. In the first nine months, revenue fell by 13.1% to EUR 465.0 million, from EUR 535.1 million in the same period last year. Adjusted EBITDA stood at minus EUR 44.3 million, compared with minus EUR 16.9 million.
Management aims to achieve a turnaround through the Horizon programme. By the end of September, Evotec had achieved more than 20% of its targeted annual savings of EUR 75 million, with between 20 and 30% planned for 2026. Around half of the job cuts have been completed. Three of the four sites are scheduled to close by the end of the year, and the fourth in the first quarter of 2027. Management confirmed its guidance for 2026. Revenue is expected to be between EUR 570 million and EUR 610 million, with adjusted EBITDA between minus EUR 70 million and minus EUR 105 million.
One bright spot is the collaboration with Vertex. The company has selected Evotec for the commercial manufacturing of the active ingredient povetacicept at the J.POD site in Redmond. If povetacicept receives approval and its market launch is successful, it could become an additional revenue generator. A share buyback of up to 365,000 shares and up to EUR 2,000,000 has been running from November 10 through December 18, exclusively for employee share programmes. On November 16, a new grant of USD 2.9 million from the Gates Foundation was added, extending a project that has been running since 2023 by 3 years. It uses human stem cells to identify risks that new drug candidates pose to prenatal development early on. The direction is right.
Vidac Pharma – trial data as a potential turning point
On November 9, Vidac Pharma presented the first results from the phase 2b trial of the investigational drug VDA-1102. It is applied to the skin and is intended to treat highly proliferative actinic keratoses. With VDA-1102, the proportion of participants examined who had a grade III marker lesion fell from 76.9% at baseline to 37.5% at week 12. With placebo, it declined from 46.2% to 44.4%. That is a respectable result. In the VDA-1102 group, 12 of 18 measurable grade III lesions were assigned a lower grade.
The trial was randomised, double-blind and placebo-controlled, meaning participants did not know which treatment they were receiving. In Germany, 39 participants received either VDA-1102 (26) or placebo (13) in a 2-to-1 ratio over 12 weeks. In addition to clinical assessment and safety monitoring, a skin imaging examination was used. The primary endpoint was the modified High-PRO score of the marker lesion at week 12. Two participants receiving VDA-1102 achieved a score of zero, compared with none receiving placebo. No serious adverse events were reported in the VDA-1102 group.
Next, the company will review the full dataset with clinical and statistical advisers, after which it will prepare a comprehensive clinical study report. So far, an initial analysis of the top-line data is available. The company points out that the small sample size limits statistical power. The data are also intended to help prepare an endpoint summary for a potential Phase 3 trial. If the full report confirms the findings of the initial analysis, Vidac Pharma could plan its next steps on a solid evidential basis. This would turn preliminary indications into a case for advancing to the next stage of clinical development. For now, VDA-1102 remains an investigational drug.
Novo Nordisk – higher guidance, new approval, and a warning
On November 4, Novo Nordisk reported third-quarter revenue of DKK 79,195 million, up 4% at constant exchange rates. Adjusted operating profit rose by 27% at constant exchange rates to DKK 31,720 million; the comparative quarter included restructuring costs of around DKK 9 billion. Reported profit fell by 9% at constant exchange rates to DKK 23,011 million, weighed down by non-cash impairment charges of DKK 8.7 billion for ziltivekimab and the production network. The group raised its 2026 guidance. It now expects adjusted revenue and profit growth of minus 2 to plus 2%, compared with minus 6 to 0% previously.
Wegovy in tablet form is performing well. It generated DKK 5,394 million in the third quarter and had been launched in the US, the United Arab Emirates, the UK and Germany by the end of the quarter. It is now in eight markets. In the REDEFINE 9 trial, participants receiving CagriSema lost 21.0% of their weight after 68 weeks, compared with 2.0% with placebo. In adults with obesity and type 2 diabetes in REIMAGINE 5, weight loss after 60 weeks was 12.4% with CagriSema and 9.1% with tirzepatide 5 mg. The US launch of CagriSema is planned for early 2027, subject to approval.
On November 13, the European Commission approved Frehemgo (denecimig) for routine prophylaxis in haemophilia A, in adults and children, with and without inhibitors. There are three dosing regimens: monthly, every two weeks or weekly. Novo Nordisk announced on October 2 that the FDA had extended its review in the US because of ongoing remedial work at a manufacturing facility; it did not cite any efficacy or safety deficiencies. The developments of November 9 remain a burden. Since then, the FDA has required all GLP-1 medicines to carry a warning about a potentially increased risk of NAION, a rare optic nerve disorder that may cause vision loss. However, Novo Nordisk sees no proven causal link.
Conclusion
All three companies have recently delivered tangible results, but their implications differ. Evotec has narrowed its quarterly loss, although revenue for the first nine months is down 13.1% year on year. Vidac Pharma has presented initial clinical data, showing some improvements in patients. If the full report confirms these findings, a Phase 3 trial could move closer. Novo Nordisk has raised its guidance and secured EU approval for Frehemgo, but still has to contend with the FDA warning. The progress is tangible, but the turnaround has yet to materialise.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as “Relevant Persons”) currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a “Transaction”). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
In this respect, there is a concrete conflict of interest in the reporting on the companies.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is also a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.